Welcome to our dedicated page for Lifeloc Technologies news (Ticker: LCTC), a resource for investors and traders seeking the latest updates and insights on Lifeloc Technologies stock.
Lifeloc Technologies, Inc. develops and manufactures breath alcohol testing devices and drug detection solutions for workplace, law enforcement, corrections and international customers. Company news commonly covers annual and quarterly operating results, revenue trends, gross margin, research and development spending, and capital actions tied to product development.
Updates also focus on the company’s SpinDetect™ Centrifugal Drug Analyzer, a compact, microfluidic-based drug screening platform under development from licensed SpinDx™ technology. Recurring announcements include product demonstrations, industry conference presentations, financing activity, and progress in portable alcohol detection and drug screening technologies.
Lifeloc Technologies, Inc. (LCTC) reported a successful 2021 financial year, achieving net revenue of $7.054 million and after-tax profit of $676 thousand, compared to a net loss of $922 thousand in 2020. The revenue growth of 11% reflects a recovery from pandemic lows. Key developments include a 65% sales increase for new LX9 and LT7 devices and the refinancing of debt to a 2.95% interest rate. The company is advancing the SpinDx technology platform and anticipates further sales growth driven by innovative product releases.
Lifeloc Technologies (OTC: LCTC) reported third-quarter financial results for 2021, showcasing a 21% revenue increase to $1.887 million and net income of $523 thousand ($0.21 per diluted share). This contrasts with Q3 2020, which had revenues of $1.555 million and a net loss of $(213) thousand. The first nine months of 2021 yielded $5.427 million in revenue and a net income of $816 thousand, bolstered by PPP loan forgiveness totaling $936 thousand. The company is optimistic about new product launches, particularly the LX9 and LT7 devices, poised to meet modern market needs, as well as the upcoming R.A.D.A.R. 200 device and SpinDx platform.
Lifeloc Technologies, Inc. (OTC: LCTC) reported its second quarter financial results for 2021, showing a net revenue of $1.730 million and a net loss of $(110) thousand, an improvement from a loss of $(350) thousand in Q2 2020. Revenue increased 31% year-over-year as demand recovers post-COVID-19. For the first six months, net revenue was $3.539 million with a net profit of $294 thousand, aided by a forgivable SBA PPP loan of $465 thousand. Lifeloc is focusing on growth opportunities through new product developments, including the LX9 and LT7 devices.
Lifeloc Technologies (OTC: LCTC) reported Q1 2021 net revenue of $1.810 million with a net income of $403 thousand, or $0.16 per diluted share. This marks a 10% decline in revenue compared to Q1 2020 due to the COVID-19 pandemic. The company received and successfully applied for forgiveness on a $465 thousand SBA PPP loan, and also secured a second loan of $471 thousand. The new L-series products, certified to SAI's standards, are driving market penetration. Lifeloc is focused on developing the SpinDx™ technology and expanding its monitoring and drug detection capabilities.
Lifeloc Technologies (OTC: LCTC) reported its 2020 financial results, revealing a net revenue of $6.357 million, down 27% from 2019's $8.752 million. The company incurred a net loss of $922,000, or $0.38 per diluted share, attributed to the impacts of the COVID-19 pandemic. Despite challenges, Lifeloc received $465,000 in PPP loan forgiveness and launched new products like the LX9 and LT7 devices. The company aims to prioritize the commercialization of the SpinDx technology, enhancing its portfolio in alcohol and drug detection.